Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Policy / Regulatory

Jiangsu Launches Sunshine Procurement Platform for Drugs and Medical Consumables

Fineline Cube Oct 10, 2022

Jiangsu province has launched its drugs and medical consumables sunshine procurement services website, providing a...

Company Drug

Merck’s Keytruda Gains 9th Indication Approval in China for Hepatocellular Carcinoma

Fineline Cube Oct 10, 2022

US major Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab)...

Company Deals

Convalife and Jointown Partner for Global Drug Development and Commercialization

Fineline Cube Oct 9, 2022

Shanghai-based Convalife Pharmaceuticals has entered into a strategic partnership with fellow Chinese firm Jointown Pharmaceutical...

Company Drug

Eli Lilly’s Retevmo Wins First China Approvals for RET-Driven Cancers

Fineline Cube Oct 9, 2022

Eli Lilly & Co (NYSE: LLY) has secured its first approvals in China for Retevmo...

Company Deals

VectorBuilder Raises $56.6M in Series C to Expand Life Science R&D

Fineline Cube Oct 9, 2022

Guangzhou-based VectorBuilder, a genetic engineering specialist incubated by the state-owned Guangzhou Industrial Investment and Capital...

Company Policy / Regulatory

WuXi Biologics Removed from US Unverified List Amid Ongoing Restrictions

Fineline Cube Oct 9, 2022

The US Commerce Department’s Bureau of Industry and Security (BIS) has updated its Unverified List...

Company Policy / Regulatory

India Launches Anti-Dumping Investigation Against Chinese Imports of Metronidazole

Fineline Cube Oct 9, 2022

The Union Ministry of Commerce and Industry in India has initiated an anti-dumping investigation into...

Policy / Regulatory

China’s NMPA Proposes Reforms to Enhance Radiopharmaceutical Review and Approval

Fineline Cube Oct 9, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Opinions on Reforming...

Company Drug

Ark Biosciences’ Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection

Fineline Cube Oct 9, 2022

China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its...

Company Drug

Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC

Fineline Cube Oct 9, 2022

US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2...

Company Drug

Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes

Fineline Cube Oct 9, 2022

China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been...

Company Drug Medical Device

Allergan Aesthetics Launches Juvederm Volite in China’s Boao Lecheng

Fineline Cube Oct 9, 2022

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite...

Company Deals

Shanghai Lange Medtech Partners with Yantai Desheng for Fish-Derived Rotator Cuff Patch

Fineline Cube Oct 9, 2022

China-based Shanghai Lange Medtech Co., Ltd. has entered into a partnership with compatriot firm Yantai...

Company Deals

Roche Boosts China Investment with Additional RMB 250 Million

Fineline Cube Oct 9, 2022

Swiss pharmaceutical giant Roche (SWX: ROG) has pledged to invest an additional RMB 250 million...

Company Medical Device

Boston Scientific Launches Disposable RF Electrode for Chronic Pain in China

Fineline Cube Oct 8, 2022

Boston Scientific Corporation (NYSE: BSX), a US-based medical device company, has announced the official market...

Company Deals Digital R&D

Rundo Med-Tech Partners with Baidu to Advance Digital Clinical Trials

Fineline Cube Oct 8, 2022

Shanghai-based Contract Research Organization (CRO) Rundo Pharmaceutical R&D (Shanghai) Co., Ltd (Rundo Med-Tech) has entered...

Policy / Regulatory

China’s NMPA Releases 60th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Oct 8, 2022

The National Medical Products Administration (NMPA) has released the 60th batch of reference drugs for...

Company Deals

China Medical System Licenses Botulinum Toxin from South Korea’s BMI Korea

Fineline Cube Oct 8, 2022

China Medical System Holdings (CMS; HKG: 0867) has announced the establishment of a licensing agreement...

Company Drug

Junshi Biosciences Launches PD-1 Inhibitor Tuoyi for Advanced NSCLC in China

Fineline Cube Oct 8, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has held a national market...

Company Deals

Betta Pharmaceuticals Raises $140.5M for Drug Industrialization Base in Zhejiang

Fineline Cube Oct 8, 2022

China’s Betta Pharmaceuticals Co., Ltd. (SHE: 300558) plans to raise RMB 1 billion ($140.5 million)...

Posts pagination

1 … 641 642 643 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.